Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition

Recent increased adverse cardiovascular events observed with selective cyclooxygenase-2 (COX-2) inhibition led to the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra), but the mechanisms underlying these atherothrombotic events remain unclear. Prostacyclin is the major endproduct of COX-2 in...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Arehart, Eric, Stitham, Jeremiah, Asselbergs, Folkert W., Douville, Karen, MacKenzie, Todd, Fetalvero, Kristina M., Gleim, Scott, Kasza, Zsolt, Rao, Yamini, Martel, Laurie, Segel, Sharon, Robb, John, Kaplan, Aaron, Simons, Michael, Powell, Richard J., Moore, Jason H., Rimm, Eric B., Martin, Kathleen A., Hwa, John
格式: Artigo
語言:Inglês
出版: 2008
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793685/
https://ncbi.nlm.nih.gov/pubmed/18323528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.107.165936
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍